OncoMatch/Clinical Trials/NCT06764017

CHiR Therapy for Elderly DLBCL Intolerant to Chemo

Is NCT06764017 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies CHiR-DEL for diffuse large b-cell lymphoma.

Phase 2RecruitingFirst Affiliated Hospital of Ningbo UniversityNCT06764017Data as of May 2026

Treatment: CHiR-DEL — The objective of exploring the application of CHiR is to evaluate its therapeutic efficacy and safety in newly diagnosed elderly patients with diffuse large B-cell lymphoma (DLBCL) aged 70 and above, and to investigate the genetic subtypes that may benefit from CHiR. The primary endpoint is the complete remission rate (CRR) at the end of 8 cycles.

Check if I qualify

Extracted eligibility criteria

Cancer type

Diffuse Large B-Cell Lymphoma

Non-Hodgkin Lymphoma

Biomarker criteria

Required: CD20 positive

Histologically confirmed CD20-positive diffuse large B-cell lymphoma

Required: MYC overexpression (≥ 40% by immunohistochemistry)

Immunohistochemically confirmed positive expression of MYC (MYC ≥ 40% by immunohistochemistry)

Required: BCL2 overexpression (≥ 50% by immunohistochemistry)

Immunohistochemically confirmed positive expression of BCL2 (BCL2 ≥ 50% by immunohistochemistry)

Performance status

ECOG 0–3(Limited self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Kidney function

creatinine < 2 times the upper limit of normal (ULN)

Liver function

ALT/AST < 2.5 ULN; total bilirubin < 2 ULN

Cardiac function

Cardiac, hepatic, and renal function: creatinine < 2 times the upper limit of normal (ULN); ALT (alanine aminotransferase)/AST (aspartate aminotransferase) < 2.5 ULN; total bilirubin < 2 ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify